New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Atossa Therapeutics advances Z-endoxifen for ER+/HER2- metastatic breast cancer, receiving FDA support for dose optimization ...

Panelists discuss how future research priorities include developing predictive biomarkers, exploring quadruple therapy ...

During a live event, Nathan Denlinger, DO, MS, discussed bridging therapy and patient barriers to CAR T-cell therapy.

FDA grants fast track designation to CLD-201, an innovative therapy for soft tissue sarcoma, enhancing its development and ...

Jacob Sands, MD, discusses the data that support the FDA accelerated approval of Dato-DXd in EGFR-positive non–small cell ...

Pirtobrutinib shows promising results in treating CLL, outperforming ibrutinib in a pivotal phase 3 trial, paving the way for ...

Early data from the DURIPANC study shows promising safety and survival benefits of rintatolimod and durvalumab for metastatic ...

New long-term data highlights the effectiveness and safety of ivosidenib with azacitidine for treating IDH1-mutated AML, ...

In an interview with Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer Institute, discusses the ...

The oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 revealed a manageable safety profile in relapsed ...

Panelists discuss how future directions in chronic lymphocytic leukemia (CLL) treatment include promising developments with ...